Novel therapeutic agents in clinical development for systemic lupus erythematosus

• Published in: BMC medicine Vol. 11; no. 1; p. 120
• Main Authors: Jordan, Natasha, Lutalo, Pamela M K, D'Cruz, David P
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 03.05.2013; BioMed Central
• Subjects: Angiogenesis Inhibitors - pharmacology; Angiogenesis Inhibitors - therapeutic use; Animals; Autoimmune diseases; B cells; B-Lymphocytes - drug effects; B-Lymphocytes - immunology; Biological Factors - pharmacology; Biological Factors - therapeutic use; Biological products industry; Biological response modifiers; Care and treatment; Clinical trials; Clinical Trials as Topic - trends; Dosage and administration; Drug therapy; Humans; Immune system; Immunosuppressive Agents - pharmacology; Immunosuppressive Agents - therapeutic use; Interferon; Kidney diseases; Lupus; Lupus Erythematosus, Systemic - diagnosis; Lupus Erythematosus, Systemic - drug therapy; Lupus Erythematosus, Systemic - immunology; Monoclonal antibodies; Mortality; Nephritis; Product development; Review; Systemic lupus erythematosus; T cells

Conventional immunosuppressive therapies have radically transformed patient survival in systemic lupus erythematosus (SLE), but their use is associated with considerable toxicity and a substantial proportion of patients remain refractory to treatment. A more comprehensive understanding of the comple...